Erratum: Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease (European Journal of Clinical Nutrition (2013) 67 (264-269) DOI: 10.1038/ejcn.2012.217);Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease

European Journal of Clinical Nutrition

Volumn 67, Issue 3, 2013, Pages 264-269

  Alvarez, J A ^a   Zughaier, S M ^a   Law, J ^a   Hao, L ^a   Wasse, H ^a   Ziegler, T R ^a   Tangpricha, V ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

cathelicidin; chronic kidney disease; cytokines; inflammation; monocyte chemoattractant protein 1; vitamin D

Indexed keywords

BIOLOGICAL MARKER; CALCITRIOL; CATHELICIDIN; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL;

PSEUDOMONAS;

EID: 84875228448     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2013.190     Document Type: Erratum

References (45)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201.
2. Judd SE, Tangpricha V. Vitamin D therapy and cardiovascular health. Curr Hypertens Rep 2011; 13: 187-191.
3. Stinghen AE, Bucharles S, Riella MC, Pecoits-Filho R. Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif 2010; 29: 114-120.
4. Sterling KA, Eftekhari P, Girndt M, Kimmel PL, Raj DS. The immunoregulatory function of vitamin D: implications in chronic kidney disease. Nat Rev Nephrol 2012; 8: 403-412.
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
6. Wang HE, Gamboa C, Warnock DG, Muntner P. Chronic kidney disease and risk of death from infection. Am J Nephrol 2011; 34: 330-336.
7. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188: 2127-2135.
8. Equils O, Naiki Y, Shapiro AM, Michelsen K, Lu D, Adams J et al. 1, 25-Dihydrox-yvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol 2006; 143: 58-64.
9. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010; 88: 441-450.
10. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-2912.
11. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374-382.
12. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31: 2253-2261.
13. Naves-Díaz M, Álvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
14. Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K et al. High-dose cholecalciferol reduces parathryroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672-679.
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
16. Zughaier SM, Tzeng YL, Zimmer SM, Datta A, Carlson RW, Stephens DS. Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun 2004; 72: 371-380.
17. Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS. Differential induction of the toll-like receptor 4-MyD88-dependent and-independent signaling pathways by endotoxins. Infect Immun 2005; 73: 2940-2950.
18. Kang YS, Cha JJ, Hyun YY, Cha DR. Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments. Expert Opin Investig Drugs 2011; 20: 745-756.
19. Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697-F701.
20. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690-695.
21. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010; 411: 1570-1579.
22. 3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human pre-adipocytes. Int J Obes (Lond) 2012; e-pub ahead of print 17 April 2012; doi:10.1038/ijo.2012.53.
23. Lorente-Cebrián S, Eriksson A, Dunlop T, Mejhert N, Dahlman I, Åström G et al. Differential effects of 1a, 25- dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr 2012; 51: 335-342.
24. 3 inhibits proliferation and decreases production of monocyte che-moattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine (Phila Pa 1976) 2008; 33: 755-765.
25. 3 targeting of NF-kB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193-201.
26. Zhu KJ, Shen QY, Zheng M, Mrowietz U. Effects of calcitriol and its analogues on interaction of MCP-1 and monocyte derived dendritic cells in vitro. Acta Pharmacol Sin 2001; 22: 62-65.
27. 3 differentially regulates IL-1a-stimulated IL-8 and MCP-1 mRNA expression and chemokine secretion by human primary proximal tubular epithelial cells. Exp Nephrol 2001; 9: 223-228.
28. 3: effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. J Bone Miner Res 2011; 27: 160-169.
29. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD et al. Oral chole-calciferol decreases albuminuria and urinary TGF-b1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011; 80: 851-860.
30. Jorde R, Sneve M, Torjesen PA, Figenschau Y, Gøransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010; 50: 175-180.
31. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353-361.
32. Bucharles S, Barberato SH, Stinghen AE, Gruber B, Piekala L, Dambiski AC et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr 2012; 22: 284-291.
33. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905-911.
34. McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros 2011; 10: 428-434.
35. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S et al. Vitamin D is required for IFN-g-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3: 104ra102.
36. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
37. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012; 109: 15449-15454.
38. 3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-250.
39. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91: 1255-1260.
40. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009; 15: 438-449.
41. 3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308: 1333-1339.
42. Soni SS, Cruz D, Bobek I, Chionh CY, Nalesso F, Lentini P et al. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol 2010; 42: 141-150.
43. Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7: 28.
44. Rudnicki M, Kerschbaum J, Hausdorfer J, Mayer G, Kö nig P. Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin D. Perit Dial Int 2010; 30: 541-548.
45. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF et al. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 2009; 182: 4289-4295.